Browsing Tag
Fidelity Management & Research
4 posts
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
Dragoneer to take event technology provider Cvent public in $5.3bn deal
Cvent, an enterprise event technology provider, is set to go public through a $5.3 billion merger deal with…
Instacart bags $265m in new funding for online grocery delivery service
Online grocery delivery company Instacart has raised $265 million in a new financing round to more than double…
Element Biosciences raises $80m for genomic sequencing solutions
Californian biotechnology startup Element Biosciences, which focuses on developing genomic sequencing solutions for research and diagnostic markets, has…